GGrantIndex
← Leaderboards

Simon Fraser University

Burnaby, BC

Compare ↔
$34,364,803
Total funding
37
Grants

Funding over time

peak $3.5M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$31,750,149 · 25
DOD$2,602,809 · 11
NSF$11,845 · 1

By mechanism

R01$21,477,732 · 9
U01$6,709,470 · 1
R21$3,197,895 · 11
—$2,614,654 · 12
F32$133,120 · 1
R03$122,271 · 1

Investigators at Simon Fraser University

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

1Ryan McNeil$4,391,3484 gr2Will Small$872,0081 gr3Zabrina Brumme$100,0671 gr4Arthur Fu Yan Poon$100,0671 gr5Mark Alan Brockman$100,0671 gr

All-Time

Most funded here, all years

1Bohdan Nosyk$8,655,7184 gr2Ryan McNeil$4,391,3484 gr3Ralph Alphonso Pantophlet$4,351,1513 gr4Jamie K Scott$2,624,2317 gr5Robert S Hogg$2,307,8832 gr6Will Small$872,0081 gr7Jose Nieva$680,3611 gr8Felix J Breden$428,4003 gr

Largest grants

Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDS$1,388,180
U01 · FY2020 · DA
Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDS$1,361,945
U01 · FY2024 · DA
Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDS$1,361,945
U01 · FY2022 · DA
Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDS$1,298,700
U01 · FY2021 · DA
Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDS$1,298,700
U01 · FY2023 · DA
Vaccines that Replicate the Neutralization-Competent Structure of the gp41 MPER$701,154
R01 · FY2012 · AI
Vaccines that Replicate the Neutralization-Competent Structure of the gp41 MPER$693,593
R01 · FY2015 · AI
Vaccines that Replicate the Neutralization-Competent Structure of the gp41 MPER$678,372
R01 · FY2014 · AI
Vaccines that Replicate the Neutralization-Competent Structure of the gp41 MPER$648,324
R01 · FY2013 · AI
DEVELOPMENT OF FERROELECTRIC MATERIALS WITH ENHANCED PIEZOELECTRIC AND OPTICAL PROPERTIES VIA DOMAIN ENGINEERING FOR ELECTROMECHANICAL TRANSDUCER APPL$596,250
· FY2021 · Department of the Navy
HIGH-PERFORMANCE PIEZO- AND FERROELECTRIC MATERIALS FOR ELECTROMECHANICAL TRANSDUCER APPLICATIONS$594,199
· FY2014 · Department of the Navy
Localized economic modeling to support implementation of the Ending the HIV Epidemic initiative$563,879
R01 · FY2021 · DA
Localized economic modeling to support implementation of the Ending the HIV Epidemic initiative$550,787
R01 · FY2022 · DA
Adjuvant, mimicry and booster requirements for shepherding the development of neutralizing antibodies to the high-mannose patch on HIV-1$545,999
R01 · FY2022 · AI
Localized economic modeling to support implementation of the Ending the HIV Epidemic initiative$544,551
R01 · FY2023 · DA
Adjuvant, mimicry and booster requirements for shepherding the development of neutralizing antibodies to the high-mannose patch on HIV-1$539,999
R01 · FY2023 · AI
Synthetic bacterial analogs of mammalian oligomannose for eliciting neutralizing antibodies to the high-mannose patch on HIV Env$539,341
R01 · FY2020 · AI
Localized economic modeling to support implementation of the Ending the HIV Epidemic initiative$538,821
R01 · FY2024 · DA
Localized economic modeling to support implementation of the Ending the HIV Epidemic initiative$534,945
R01 · FY2025 · DA
Tobacco Companies, Public Policy and Global Health$515,442
R01 · FY2017 · CA